StocksDiva Bio Bin

[StocksDiva]

The NVLX presentation entitled "Cell-in-a-Box® Living Cell Encapsulation Products for Medical and Healthcare Use" given during the Clinical Trials section of the Convention's program, Dr. Günzburg reviewed the data from the early/mid-phase clinical trials that were done with the combination of Cell-in-a-Box® and the anti-cancer prodrug ifosfamide in patients with advanced inoperable pancreatic cancer; In those Phase 1 and Phase 2 clinical trials, the Cell-in-a-Box®/ifosfamide combination treatment was shown to essentially double the median survival time and percentage of one-year survivors over those seen in historical data for Gemzar® (gemcitabine), the only drug approved to date by the FDA as a single agent for the treatment of the disease. But unlike Gemzar®, Nuvilex's treatment had no serious treatment-related side effects associated with it because the dose of ifosfamide used in these trials was only one-third of that normally employed for cancer treatment. http://www.stockwatch.com/News/Item.aspx?bid=U-z10072790-U%3aNVLX-20140317&symbol=NVLX®ion=U